Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics
Authors:
- Deborah BarthelDBDeborah Barthel
- Gerd GanserGGGerd Ganser
- Rolf-Michael KuesterRKRolf-Michael Kuester
- Nils OnkenNONils Onken
- Kirsten MindenKMKirsten Minden
- Hermann Josef GirschickHGHermann Josef Girschick
- Anton HospachAHAnton Hospach
- Gerd HorneffGHGerd Horneff
- 15 September 2015
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 42 (11) , 2160-2165
Abstract
Objective. Evolving inflammatory bowel disease (IBD) is a matter of interest in patients with juvenile idiopathic arthritis (JIA) and might be associated with JIA therapy. Methods. Data from the German biologics registry (Biologika in der Kinderrheumatologie; BiKeR) from 2001 to 2013 were analyzed. Results. There were 3071 patients with 8389 patient-years (PY) of observation followed. IBD was diagnosed in 11 patients, 8 with Crohn disease and 3 with ulcerative colitis. IBD incidence in patients with JIA was 1.31/1000 PY and higher than published IBD incidences in pediatric populations. Compared with the total BiKeR cohort, patients with IBD more commonly had enthesitis-related arthritis, extended oligoarthritis, psoriatic arthritis, and also rheumatoid factor (RF)-negative polyarthritis. No IBD occurred in patients with systemic JIA or RF-positive polyarthritis. In patients treated with methotrexate (MTX), the IBD incidence was significantly lower compared with patients not treated with MTX. Etanercept (ETN) monotherapy, but not the combination of ETN and MTX, was associated with an increased incidence of IBD. Conclusion. Incidence of IBD in patients with JIA is higher than in the population. MTX turned out to be protective, even in combination with ETN.Keywords
This publication has 37 references indexed in Scilit:
- Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide seriesJoint Bone Spine, 2012
- Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with EtanerceptThe Journal of Rheumatology, 2011
- 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic featuresArthritis Care & Research, 2011
- Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximabScandinavian Journal of Rheumatology, 2010
- Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative dataGut, 2009
- Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective studyRheumatology, 2009
- Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patientsAnnals of the Rheumatic Diseases, 2008
- The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based StudyGastroenterology, 2005
- Risk factors for inflammatory bowel disease in the general populationAlimentary Pharmacology & Therapeutics, 2005
- Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAlimentary Pharmacology & Therapeutics, 2005